PT  - JOURNAL ARTICLE
AU  - Cui, Zhu
AU  - Roth, Maxwell
AU  - Averbukh, Yelena
AU  - Assa, Andrei
AU  - Ani, Azal Al
AU  - Southern, William
AU  - Gil, Morayma Reyes
AU  - Arora, Shitij
TI  - Corticosteroids and mortality in patients with severe Covid-19 who have autoantibodies
AID  - 10.1101/2021.03.19.21253005
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.19.21253005
4099  - http://medrxiv.org/content/early/2021/03/23/2021.03.19.21253005.short
4100  - http://medrxiv.org/content/early/2021/03/23/2021.03.19.21253005.full
AB  - Auto-reactivity in COVID-19 is increasingly being recognized and may identify a group of patients with inflammation severe enough to result in loss of self-tolerance. Corticosteroids are potent anti-inflammatory agents and now the standard of care for patients with severe Covid-19 requiring oxygen support/mechanical ventilation. We studied the outcomes of COVID-19 patients who demonstrated clinically identifiable auto-reactivity and received corticosteroid treatment.In this retrospective cohort study, we included 51 COVID-19 patients admitted between March 10, 2020 and May 2, 2020 who received corticosteroid treatment and also had serum sample in our institution bio-bank available for ANA and RF ELISA. Twelve patients (23.5%) had positive ANA or RF. Mortality rate among patients with positive autoantibodies was significantly higher than those without (9/12 or 75% versus 13/39 or 33.3%, p= 0.02). The high mortality rate in patients with auto-reactivity warrants further investigation and may be the subgroup where additional immunomodulation is effective.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding source to disclose.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional review board of the Albert Einstein College of Medicine.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.